Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Assets: 2014-2024

Historic Current Assets for ImmunityBio (IBRX) over the last 11 years, with Dec 2024 value amounting to $184.6 million.

  • ImmunityBio's Current Assets rose 101.96% to $329.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $329.5 million, marking a year-over-year increase of 101.96%. This contributed to the annual value of $184.6 million for FY2024, which is 37.23% down from last year.
  • According to the latest figures from FY2024, ImmunityBio's Current Assets is $184.6 million, which was down 37.23% from $294.1 million recorded in FY2023.
  • Over the past 5 years, ImmunityBio's Current Assets peaked at $334.3 million during FY2021, and registered a low of $111.7 million during FY2020.
  • In the last 3 years, ImmunityBio's Current Assets had a median value of $184.6 million in 2024 and averaged $206.4 million.
  • In the last 5 years, ImmunityBio's Current Assets skyrocketed by 199.29% in 2021 and then crashed by 57.95% in 2022.
  • ImmunityBio's Current Assets (Yearly) stood at $111.7 million in 2020, then surged by 199.29% to $334.3 million in 2021, then crashed by 57.95% to $140.6 million in 2022, then surged by 109.20% to $294.1 million in 2023, then crashed by 37.23% to $184.6 million in 2024.